Clinical efficacy of recombinant human epidermal growth factor solution in relieving pharyngeal pain after Viral cold

Read full text Summarise with VIRAT
Authors: Zhonghua Wu, Dongsheng Chen, Jianfeng Liu, Xin Wang
Cited by: 0
References: 17

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective: This study aimed to evaluate how well recombinant human epidermal growth factor (rhEGF) works in relieving throat pain caused by a viral cold. Methods: Fifty patients aged 18–70 years with mild Omicron variant SARS-CoV-2 infection, no underlying diseases, and sore throat symptoms were enrolled. They were randomly assigned to either a control group (conventional therapy) or an EGF treatment group (conventional therapy plus EGF spray). The visual analog scale (VAS) score for pain, time to onset of pain relief, duration of analgesic effect, and recovery of the posterior pharyngeal wall mucosa were compared between the two groups before and after treatment. Results: Compared with the control group, the EGF treatment group showed a significantly shorter time to pain relief, longer duration of effect, and better mucosal recovery of the posterior pharyngeal wall, with statistically significant differences. Conclusion: Topical application of recombinant human epidermal growth factor can effectively and rapidly relieve pain caused by viral pharyngitis and promote mucosal repair, demonstrating a favorable adjuvant role in the treatment of viral cold accompanied by inflammatory pharyngeal pain.

Fields of Study & Subjects

COVID-19 Clinical Research Studies Pediatric health and respiratory diseases Respiratory and Cough-Related Research

Publication details

Journal / source
Global Insights in Medicine and Nursing
Volume
2
Issue
1
Pages
1–6
Publication date
25 March 2026
Language
EN